V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Vor Biopharma. Financial results for the second quarter of 2021.

10.08.2021

GAAP net loss is -$0.50, which is $0.07 better than the same period last year.

Cash, cash equivalents and investments are $244.6 million as of June 30, 2021.